PBPK modeling to evaluate maximum tolerated doses: A case study with 3-chloroallyl alcohol

Area of Science:

• Pharmacokinetics and Toxicological Modeling
• In Vivo Genotoxicity Assessment

Background:

• Physiologically based pharmacokinetic (PBPK) models are crucial for understanding chemical toxicity.
• 3-chloroallyl alcohol (3-CAA) genotoxicity requires accurate dose-response assessment to avoid confounding factors like cytotoxicity.
• Ethanol's PBPK model provides a basis for developing a PBPK model for 3-CAA due to shared metabolic pathways (alcohol dehydrogenases).

Purpose of the Study:

• To develop a PBPK model for 3-chloroallyl alcohol (3-CAA).
• To evaluate assay designs for 3-CAA's in vivo genotoxicity.
• To assess the impact of dose route (oral gavage vs. drinking water) on 3-CAA pharmacokinetics and toxicity.

Main Methods:

• Developed a PBPK model for 3-CAA, utilizing read-across from an existing ethanol PBPK model.
• Simulated 3-CAA pharmacokinetics for oral gavage and drinking water routes.
• Evaluated key toxicokinetic parameters: maximum blood concentration (Cmax) and area under the curve (AUC).

Main Results:

• Oral gavage resulted in a 6-fold higher Cmax compared to drinking water for the same dose.
• AUC values were similar between oral gavage and drinking water routes.
• Predicted Cmax correlated strongly with severe toxicity (e.g., lethality), suggesting a role for reactive metabolites.

Conclusions:

• Drinking water administration of 3-CAA allows for higher sustained exposure without inducing severe toxicity.
• The PBPK model aids in designing genotoxicity studies that comply with regulatory guidelines (OECD, USEPA).
• PBPK modeling ensures appropriate target tissue exposure assessment, even without direct laboratory measurements.